BACKGROUND: Guidelines suggest that followup for low-grade soft tissue sarcomas should be every 3 to 6 months for 2 to 3 years and then annually, and for high-grade sarcomas every 3 to 6 months for 2 to 5 years, then every 6 months for the next 2 years, and then annually. However, there is only very limited evidence to support these strategies. QUESTIONS/PURPOSES: In a population of patients treated surgically for soft tissue sarcomas, we evaluated the (1) timing of diagnosis of local recurrences after sarcoma excision; (2) timing of diagnosis of distant metastases; and (3) the difference in those parameters based on tumor size and grade. METHODS: Patients diagnosed with soft tissue sarcomas and who underwent surgical excision between 1978 and 2008 were retrospectively reviewed. Age, histologic diagnosis, Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grade, tumor location, and size were reviewed at a mean of 6 years (range, 1 month to 30 years). We met with patients every 3 months for 5 years, every 6 months for 10 years, and then annually until 15 years after surgery. Eight hundred sixty-seven patients with a median age at diagnosis of 52 years were eligible for analysis. The incidence of local recurrence and metastases was calculated for every 2-year period and presented per 1000 person-years. RESULTS: Ninety-eight patients (11%) developed local recurrence at a median time of 19 months; 90% of patients who had local recurrences had them within 7.1 years, and 95% occurred by 8.6 years. One hundred ninety-eight patients (23%) developed distant metastases at a median time of 12 months; 90% of patients who developed metastases developed them by 4.2 years and 95% did so by 7.3 years. High-grade tumors had a higher incidence of local recurrence and metastases in first 2 years, whereas low-grade tumors recurred at a constant rate throughout the followup period. CONCLUSIONS: Followup beyond 10 years does not yield a sufficient number of local recurrences or metastases to warrant further monitoring. LEVEL OF EVIDENCE: Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence.
BACKGROUND: Guidelines suggest that followup for low-grade soft tissue sarcomas should be every 3 to 6 months for 2 to 3 years and then annually, and for high-grade sarcomas every 3 to 6 months for 2 to 5 years, then every 6 months for the next 2 years, and then annually. However, there is only very limited evidence to support these strategies. QUESTIONS/PURPOSES: In a population of patients treated surgically for soft tissue sarcomas, we evaluated the (1) timing of diagnosis of local recurrences after sarcoma excision; (2) timing of diagnosis of distant metastases; and (3) the difference in those parameters based on tumor size and grade. METHODS:Patients diagnosed with soft tissue sarcomas and who underwent surgical excision between 1978 and 2008 were retrospectively reviewed. Age, histologic diagnosis, Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grade, tumor location, and size were reviewed at a mean of 6 years (range, 1 month to 30 years). We met with patients every 3 months for 5 years, every 6 months for 10 years, and then annually until 15 years after surgery. Eight hundred sixty-seven patients with a median age at diagnosis of 52 years were eligible for analysis. The incidence of local recurrence and metastases was calculated for every 2-year period and presented per 1000 person-years. RESULTS: Ninety-eight patients (11%) developed local recurrence at a median time of 19 months; 90% of patients who had local recurrences had them within 7.1 years, and 95% occurred by 8.6 years. One hundred ninety-eight patients (23%) developed distant metastases at a median time of 12 months; 90% of patients who developed metastases developed them by 4.2 years and 95% did so by 7.3 years. High-grade tumors had a higher incidence of local recurrence and metastases in first 2 years, whereas low-grade tumors recurred at a constant rate throughout the followup period. CONCLUSIONS: Followup beyond 10 years does not yield a sufficient number of local recurrences or metastases to warrant further monitoring. LEVEL OF EVIDENCE: Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence.
Authors: Eduardo N Novais; Bahtiyar Demiralp; Joseph Alderete; Melissa C Larson; Peter S Rose; Franklin H Sim Journal: Clin Orthop Relat Res Date: 2010-11 Impact factor: 4.176
Authors: Samuel Kim; Harald C Ott; Cameron D Wright; John C Wain; Christopher Morse; Henning A Gaissert; Dean M Donahue; Douglas J Mathisen; Michael Lanuti Journal: Ann Thorac Surg Date: 2011-10-31 Impact factor: 4.330
Authors: J B Fleming; S B Cantor; D G Varma; D Holst; B W Feig; K K Hunt; S R Patel; R S Benjamin; R E Pollock; P W Pisters Journal: Cancer Date: 2001-08-15 Impact factor: 6.860
Authors: J M Coindre; P Terrier; L Guillou; V Le Doussal; F Collin; D Ranchère; X Sastre; M O Vilain; F Bonichon; B N'Guyen Bui Journal: Cancer Date: 2001-05-15 Impact factor: 6.860
Authors: C S Trovik; H C Bauer; T A Alvegård; H Anderson; C Blomqvist; O Berlin; P Gustafson; G Saeter; A Wallöe Journal: Eur J Cancer Date: 2000-04 Impact factor: 9.162
Authors: Alessandro Gronchi; Salvatore Lo Vullo; Chiara Colombo; Paola Collini; Silvia Stacchiotti; Luigi Mariani; Marco Fiore; Paolo Giovanni Casali Journal: Ann Surg Date: 2010-03 Impact factor: 12.969
Authors: D A Potter; J Glenn; T Kinsella; E Glatstein; E E Lack; C Restrepo; D E White; C A Seipp; R Wesley; S A Rosenberg Journal: J Clin Oncol Date: 1985-03 Impact factor: 44.544
Authors: Heidi M Namløs; Olga Zaikova; Bodil Bjerkehagen; Daniel Vodák; Eivind Hovig; Ola Myklebost; Kjetil Boye; Leonardo A Meza-Zepeda Journal: BMC Cancer Date: 2017-01-06 Impact factor: 4.430